Lifecore Biomedical, Inc. (LFCR)
| Market Cap | 187.69M |
| Revenue (ttm) | 157.39M |
| Net Income (ttm) | -117.90M |
| Shares Out | 30.32M |
| EPS (ttm) | -3.96 |
| PE Ratio | n/a |
| Forward PE | 28.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,272 |
| Open | 6.18 |
| Previous Close | 6.18 |
| Day's Range | 6.12 - 6.35 |
| 52-Week Range | 1.52 - 11.46 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 9.50 (+53.47%) |
| Earnings Date | Jan 9, 2024 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology... [Read more]
Full Company ProfileFinancial Performance
In 2022, LFCR's revenue was $185.79 million, an increase of 8.30% compared to the previous year's $171.55 million. Losses were -$114.68 million, 251.1% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 53.47% from the latest price.
News
Top 5 Risk Off Stocks That May Explode This Quarter - AgriFORCE Growing Systems (NASDAQ:AGRI), Bit Brother (NASDAQ:BETS)
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
Lifecore Biomedical Provides Business Update
CHASKA, Minn., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provid...
Company Reaches Favorable Resolution Regarding Previously-Disclosed Investigation of Formerly-Held Subsidiary Yucatan Foods
CHASKA, Minn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that the U.S. Department of Justice (the “DOJ”) has declined to prosecute the ...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report
CHASKA, Minn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on October 12, 2023 from the Listing Qual...
SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement
ZUG, Switzerland , Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery syste...
Lifecore Biomedical Provides Update for Development Portfolio and Timing of Delayed Filings
CHASKA, Minn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provide...
Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results
CHASKA, Minn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (Nasdaq: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”)...
Lifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CT
CHASKA, Minn., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announc...
Lifecore Biomedical Reports Third Quarter Fiscal Year 2023 Results
Going concern qualification is removed as a result of the $150 million new financing transaction announced last week Going concern qualification is removed as a result of the $150 million new financin...
Lifecore Biomedical stock climbs 19% on $150 million refinancing deal
Shares of Lifecore Biomedical on Monday climbed 19% to $6.40 in after-hours trading after the company said it secured a new $150 million financing agreement with its long-term customer Alcon.
Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan New $150 million credit arrangements include six-year credit agree...
Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announce...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
CHASKA, Minn., April 14, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on April 13, 2023 from the Listing Quali...
Lifecore Biomedical Announces Sale of Curation Foods' O Olive Oil and Vinegar® Business
CHASKA, Minn., April 06, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announ...
Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship
Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation
Lifecore Biomedical Announces Intent to Explore Strategic Alternatives
CHASKA, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announ...
Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results
Company Announces Intention to Explore Strategic Alternatives Signs Term Sheet with Key Customer to Materially Expand Commercial Relationship Expands Development Pipeline from 24 to 25 Active Projects...
Lifecore Biomedical Announces Sale of Curation Foods' Avocado Products Business
Proceeds to be used for debt paydown Proceeds to be used for debt paydown
Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report
CHASKA, Minn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), announced today that it received a notice (“Notice”) on January 11, 2023 from the Listing Qual...
Lifecore Biomedical Raises Capital with Private Placement of Convertible Preferred Stock; Amends Credit Facilities
$38.75 million Private Placement of Series A Convertible Preferred Stock to Support Working Capital and Capital Expenditures While Pursuing Ongoing Divestment Process of non-CDMO Assets
4 Cheapest Defensive Stocks You Should Think About - Hempacco (NASDAQ:HPCO), Lifecore Biomedical (NASDAQ:LFCR)
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
Lifecore Biomedical Raises Capital for Growth with Existing Stockholder
Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced the closing of a $5 million private placement ...